Stock Market Reviews

MRNA (Moderna, Inc.) News

Get the latest news, insights, and market updates on MRNA (Moderna, Inc.). Explore the news page 2 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.

• Why Is Moderna (MRNA) Stock Rocketing Higher Today
  Shares of biotechnology company Moderna (NASDAQ:MRNA) jumped 7.8% in the afternoon session after the stock's positive momentum continued as the Coalition for Epidemic Preparedness Innovations (CEPI) announced it would invest up to $54.3 million to support a pivotal Phase 3 clinical trial for the company's investigational mRNA-based pandemic influenza vaccine candidate, mRNA-1018.
  Dec 19, 2025 - $MRNA
• Down 80%, Should You Buy the Dip on Moderna?
  Your decision on whether to invest now depends to some extent on your investment strategy.
  Dec 19, 2025 - $MRNA
• CEPI to Fund Pivotal Phase 3 Trial for Moderna's mRNA Pandemic Influenza Vaccine Candidate
  Up to $54.3 million CEPI investment aims to help advance Moderna's H5 pandemic influenza vaccine candidate to licensure Partnership strengthens global preparedness against a significant pandemic threat If licensed and in the event of an influenza ...
  Dec 18, 2025 - $MRNA
• Moderna, Inc. (MRNA): A Bull Case Theory
  We came across a bullish thesis on Moderna, Inc. on Alpha Talon Investment Research’s Substack by AT Investment Research. In this article, we will summarize the bulls’ thesis on MRNA. Moderna, Inc.’s share was trading at $29.92 as of December 15th. MRNA’s trailing P/E was 7.06 according to Yahoo Finance. Moderna, Inc., a biotechnology company, provides messenger RNA medicines in the United States, Europe, and internationally. MRNA’s strategy from 2025–2030 emphasizes capital efficiency […]
  Dec 18, 2025 - $MRNA
• Why Moderna (MRNA) Stock Is Up Today
  Shares of biotechnology company Moderna (NASDAQ:MRNA) jumped 4% in the morning session after the company announced it would receive up to $54.3 million in funding from the Coalition for Epidemic Preparedness Innovations (CEPI) to advance a late-stage trial for its experimental bird flu vaccine.
  Dec 18, 2025 - $MRNA
• Moderna's $54M Lifeline: Bird Flu Bet Revived After U.S. Pullback
  With federal funding cut, Moderna finds new backers for its pandemic play--just as mRNA faces a critical test
  Dec 18, 2025 - $MRNA
• Moderna (MRNA) Valuation Check as CEPI Backs Phase 3 H5 Bird Flu Vaccine with $54.3 Million Funding
  Moderna (MRNA) is back in the spotlight after securing up to $54.3 million from CEPI to help fund a Phase 3 trial of its H5 bird flu vaccine candidate, mRNA-1018. See our latest analysis for Moderna. The CEPI funding has helped extend a short burst of momentum, with Moderna’s 1 month share price return of 23.22 percent contrasting sharply with a 1 year total shareholder return of negative 20.46 percent. This suggests sentiment is improving, but the longer term recovery story is still being...
  Dec 18, 2025 - $MRNA
• Moderna gets funding for H5 pandemic influenza vaccine
  The fresh capital provides another shot for Moderna's candidate against bird flu, which earlier this year lost its government funding.
  Dec 18, 2025 - $MRNA
• Moderna (MRNA) Stock Trades Up, Here Is Why
  Shares of biotechnology company Moderna (NASDAQ:MRNA) jumped 4% in the afternoon session after the broader biotech sector experienced a strong rebound, lifting shares of companies within the industry.
  Dec 17, 2025 - $MRNA
• Moderna to Present at the 44th Annual J.P. Morgan Healthcare Conference
  CAMBRIDGE, MA / ACCESS Newswire / December 17, 2025 / Moderna, Inc. (Nasdaq:MRNA) today announced it will present at the 44th annual J.P. Morgan Healthcare Conference on Monday, January 12th at 7:30 p.m. ET / 4:30 p.m. PT. A live webcast of the presentation ...
  Dec 17, 2025 - $MRNA